Schonfeld Strategic Advisors LLC Lowers Position in Geron Co. (NASDAQ:GERN)

Schonfeld Strategic Advisors LLC decreased its holdings in shares of Geron Co. (NASDAQ:GERN - Free Report) by 86.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 105,800 shares of the biopharmaceutical company's stock after selling 676,572 shares during the quarter. Schonfeld Strategic Advisors LLC's holdings in Geron were worth $375,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the business. Barclays PLC raised its position in shares of Geron by 114.9% during the 3rd quarter. Barclays PLC now owns 1,299,912 shares of the biopharmaceutical company's stock valued at $5,902,000 after buying an additional 694,931 shares in the last quarter. Moody National Bank Trust Division increased its stake in Geron by 76.6% during the fourth quarter. Moody National Bank Trust Division now owns 267,629 shares of the biopharmaceutical company's stock worth $947,000 after acquiring an additional 116,074 shares during the last quarter. Elmwood Wealth Management Inc. purchased a new stake in Geron during the fourth quarter valued at approximately $93,000. Rovin Capital UT ADV lifted its stake in shares of Geron by 26.9% in the 4th quarter. Rovin Capital UT ADV now owns 17,270 shares of the biopharmaceutical company's stock valued at $61,000 after purchasing an additional 3,660 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. boosted its holdings in shares of Geron by 18.1% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 403,703 shares of the biopharmaceutical company's stock worth $1,429,000 after purchasing an additional 61,819 shares during the period. Institutional investors own 73.71% of the company's stock.

Analyst Ratings Changes

Several analysts recently weighed in on GERN shares. Barclays restated an "overweight" rating and set a $4.00 price target (down previously from $9.00) on shares of Geron in a report on Thursday, February 27th. Stifel Nicolaus reduced their target price on shares of Geron from $8.00 to $4.00 and set a "buy" rating on the stock in a research note on Thursday, February 27th. Needham & Company LLC reaffirmed a "buy" rating and set a $5.00 price target on shares of Geron in a research note on Wednesday, March 12th. HC Wainwright reissued a "neutral" rating on shares of Geron in a research report on Wednesday, March 12th. Finally, Scotiabank downgraded shares of Geron from a "sector outperform" rating to a "sector perform" rating and decreased their price objective for the stock from $4.00 to $1.50 in a research note on Thursday, May 8th. One analyst has rated the stock with a sell rating, three have issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Geron presently has a consensus rating of "Moderate Buy" and a consensus price target of $5.06.

Geron Trading Up 2.1%

Geron stock traded up $0.03 during trading hours on Friday, hitting $1.24. The company had a trading volume of 2,128,082 shares, compared to its average volume of 13,856,628. The firm has a market cap of $786.59 million, a P/E ratio of -3.86 and a beta of 0.76. The company has a 50-day moving average price of $1.45 and a two-hundred day moving average price of $2.66. Geron Co. has a 1 year low of $1.17 and a 1 year high of $5.34. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89.

Geron (NASDAQ:GERN - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.04) by $0.01. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The firm had revenue of $39.60 million during the quarter, compared to analyst estimates of $49.88 million. During the same quarter in the previous year, the business earned ($0.07) earnings per share. Geron's quarterly revenue was up 12927.3% on a year-over-year basis. On average, sell-side analysts anticipate that Geron Co. will post -0.25 earnings per share for the current year.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.